|
1. http://www.cancer.gov/cancertopics/types/ovarian. See also http://www.mayoclinic.com/health/ovarian-cancer
2. Nossov V, Amneus M, Su F, et al. The early detection of ovarian cancer: from traditional methods to proteomics. Can we really do better than serum CA-125? Am J Obstet Gynecol. 2008 199:215-23, 2008
3. Fung MF, Bryson P, Johnston M, et al. Screening postmenopausal women for ovarian cancer: a systematic review. J Obstet Gynaecol Can. 26:717-28, 2004.
4. Menon U, Gentry-Maharaj A, Hallett R, et al. Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol. 10:327-40, 2009.
5. www.cancer.gov/cancertopics/types/colon. See also www.mayoclinic.com/health
6. Atkin W. Options for screening for colorectal cancer. Scand J Gastroenterol Suppl. 237:13-6, 2003.
7. Hundt S, Haug U, Brenner H. Comparative evaluation of immunochemical fecal occult blood tests for colorectal adenoma detection. Ann Intern Med. 150:162-9, 2009.
8. American Cancer Society. Breast Cancer Quick Facts. www.cancer.org/docroot/GI/content/GI_2_9_Breast_Cancer_Quick_Facts. See also Smith RA, Saslow D, Sawyer KA, et al. American Cancer Society Guidelines for Breast Cancer Screening: Update 2003. CA Cancer J Clin. 2003;53:141-169.
9. Alexe G, Monaco J, Doyle S, Basavanhally A, et al. Towards Improved Cancer Diagnosis and Prognosis using Analysis of Gene Expression Data and Computer Aided Imaging. Exp Biol Med (Maywood). Jun 2, 2009.
10. Roukos DH, Murray S, Briasoulis E. Molecular genetic tools shape a roadmap towards a more accurate prognostic prediction and personalized management of cancer. Cancer Biol Ther. 6:308-12, 2007.
11. Kim BK, Lee JW, Park PJ, The multiplex bead array approach to identifying serum biomarkers associated with breast cancer. Breast Cancer Res. 11:R22, 2009.
12. Moul JW. Population screening for prostate cancer and emerging concepts for young men. Clin Prostate Cancer. 2003 Sep;2(2):87-97.
13. www.davinciprostatectomy.com/about-prostate-cancer/index.aspx?id-guro&gclid=CJ-WnobCwZsCFQRkswodbx2PAQ. See also www.mayoclinic.com/health/prostate-cancer.
14. Sonya Parpart, et al. Sensitivity and Specificity in Prostate Cancer Screening Methods and Strategies The Journal of Young Investigators: An Undergraduate, Peer-Reviewed Science Journal 19 (12), June 2009.
15. American Cancer Society. Cancer Facts & Figures 2005. Atlanta, GA: American Cancer Society; 2005.
16. Fleshner NE, Lawrentschuk N. Risk of developing prostate cancer in the future: overview of prognostic biomarkers. Urology. 73(5 Suppl):S21-7, 2009.
17. Mutlu N, Complexed prostate specific antigen: better test in the diagnosis of prostate cancer for the clinically relevant 2.5-4 ng/ml total PSA range. Can J Urol. 16: 4558-67, 2009.
18. Oesterling JEJ Urol. Free, complexed and total serum prostate specific antigen: the establishment of appropriate reference ranges for their concentrations and ratios. J. Urol. 154:1090-1095, 1995.
19. Roddam AW, Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA level of 2-10 ng/ml: systematic review and meta-analysis. Eur Urol. 48:386-99, 2005.
20. Rosenblatt, Kevin. et. al. "Serum Proteomics in Cancer Diagnosis and Management." Annual Review of Medicine. 55, 97-112, 2004.
21. Mikolajczyk SD, Rittenhouse HG. Pro PSA: a more cancer specific form of prostate specific antigen for the early detection of prostate cancer. Keio J Med. 52:86-91, 2003. See also Mikolajczyk SD, Catalona WJ, Evans CL, et al. Proenzyme forms of prostate-specific antigen in serum improve the detection of prostate cancer.
|